Andrew Booth, Chief Financial Officer at AbCellera Biologics Inc. (ABCL), bought 42,600 shares at $3.42 ($146K) on 2026-02-27, disclosed to the SEC on 2026-02-27.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| Filing → |
| ABCL | BUY | 2022-05-16 | $492K | — | Filing → |
| ABCL | BUY | 2021-11-15 | $993K | — | Filing → |
| ABCL | SELL | 2021-06-10 | $30.6M | — | Filing → |